Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...
Kendall Markovic was a leader on and off the field when Hutchinson’s girls and boys soccer teams played host to Rockford Tuesday. The senior co-captain started as a mid-fielder, plus helped ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...
Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...
The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback